Press Releases

Date Title
November 30, 2020 Progenity Announces Proposed Convertible Senior Notes Offering
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private offering to qualified institutional
November 30, 2020 Progenity Announces Proposed Public Offering of Common Stock
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it has commenced an underwritten public offering of $25
November 20, 2020 New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™ Test
High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia SAN DIEGO, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular
November 17, 2020 Progenity to Present at 2020 San Antonio Breast Cancer Virtual Symposium
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, will be presenting at the San Antonio Breast Cancer Virtual Symposium (SABCS) set to take
November 16, 2020 Progenity to Participate in the 32nd Annual Piper Sandler Healthcare Conference
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of
November 13, 2020 Progenity to Host Preeclampsia Virtual R&D Day on November 20, 2020
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will host a Preeclampsia Virtual R&D Day on November 20, 2020 from
November 9, 2020 Progenity Provides Corporate Updates and Reports Third Quarter 2020 Financial Results
Reported 8 4 thousand tests in the third quarter , up 12% compared to the second quarter Achieved a p reeclampsia t est a nalytical v erification m ilestone Management will host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SAN DIEGO, Nov.
November 6, 2020 Progenity Announces Encouraging Preclinical Data Supporting the Potential of the Company’s Oral Drug Delivery System in Targeting the Colon
SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, is pleased to announce positive preliminary preclinical data regarding the performance of
November 3, 2020 Progenity to Report Third Quarter 2020 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report third quarter 2020 financial results on Monday, November
October 29, 2020 Progenity Announces Successful Achievement of its Preeclampsia Test Analytical Verification Milestone
Announces Expansion of its COVID-19 Testing Offering Provides Preliminary Third Quarter 2020 Financial Update SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular
Displaying 31 - 40 of 74